« Back
Home /
SB-273005

SB-273005

Item no.	HY-19307-100mg
Manufacturer	MedChem Express
CASRN	205678-31-5
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.94
Citations	[1]Badger AM, et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 2001 Jan;44(1):128-37. \|[2]Rehm S, et al. Novel vascular lesions in mice given a non-peptide vitronectin receptor antagonist. Toxicol Pathol. 2007 Dec;35(7):958-71. \|[3]Parker SJ, et al. Proteomics reveals Rictor as a noncanonical TGF-β signaling target during aneurysm progression in Marfan mice. Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1112-H1126.\|[4]Wang S, et al. SB-273005, an antagonist of αvβ3 integrin, reduces the production of Th2 cells and cytokine IL-10 in pregnant mice. Exp Ther Med. 2014 Jun;7(6):1677-1682. \|[5]Hoffman SJ, et al. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. J Pharmacol Exp Ther. 2002 Jul;302(1):205-11.
Smiles	O=C(O)C[C@H]1C(N(CC(F)(F)F)CC2=CC(OCCC3=NC(NC)=CC=C3)=CC=C2C1)=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Integrin; Interleukin Related
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	451.44
Product Description	SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with Ki values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. [1][2][3][4][5].
Manufacturer - Research Area	Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Cytoskeleton; Immunology/Inflammation
Isoform	IL-10; αvβ3; αvβ5
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19307-100mg-safety-datasheet.pdf